FDA approves Ocrevus Zunovo as the first and only twice-a-year 10-minute subcutaneous injection for people with relapsing and progressive multiple sclerosis
- OCREVUS ZUNOVO is approved for relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS).
- It is the first twice-a-year, 10-minute subcutaneous injection for MS, offering more treatment options.
- Approval is based on Phase III OCARINA II trial data showing non-inferior efficacy and safety compared to IV formulation.
- OCREVUS ZUNOVO demonstrated 97% suppression of relapse activity and MRI lesions through 48 weeks.
Read more
